OncLive Insights

Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.

Expert oncologists discuss the hormone receptor–positive (HR+) breast cancer treatment landscape and their suggested approaches to treating patients in both the early and metastatic disease settings.

An expert panel discusses recent advances in the treatment of Stage I-III NSCLC and their impact on clinical practice.

Expert oncologist Martin Dietrich, MD, PhD, shares his excitement for an upcoming program wherein he and Meghan Mooradian, MD, highlight the evolving role of immunotherapy and biomarker-driven therapy in non-small cell lung cancer.

Expert perspectives on the prevention and treatment of tumor lysis syndrome (TLS) in patients on therapy for cancer.

Shaji Kumar, MD, and Krina Patel, MD, discuss key updates in the diagnosis and treatment of multiple myeloma. Jenny Ahlstrom, a patient, and Bonnie Falbo, a caregiver and patient advocate, share their personal journeys with multiple myeloma.

Expert oncologists work together to review the current treatment paradigm for metastatic castration-resistant prostate cancer in the context of clinical trials and real-world experience.

Expert perspectives on the advent of KRAS G12C mutations in non–small cell lung cancer, with a focus on the development of targeted therapies in this setting.

Brian Hill, MD, PhD and Lori Leslie, MD, discuss their respective treatment approaches to relapsed/refractory follicular lymphoma (R/R FL), sharing patient cases, reviewing treatment options for patients with the disease, and providing clinical advice for community-based oncologists.

Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.

Joseph Mikhael, MD, and Craig Cole, MD, discuss the substantial disparities in incidence and survival rates between patient populations with multiple myeloma, especially between Black and white Americans.

A panel of oncologists share insights on molecular testing in non-small cell lung cancer (NSCLC) and how they integrate and interpret the results to optimize treatment selection for their patients.

Sponsored in part by Takeda Oncology. Content independently developed by OncLive.

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic endometrial cancer (mEC).

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Satya (Nanu) Das, MD, MSCI, Rodney Pommier, MD, and Jerome Zacks, MD, discuss how patients with neuroendocrine tumors progress to carcinoid syndrome and carcinoid heart disease, and how strategies for management have changed after key clinical trial data.

Funding provided by TerSera Therapeutics LLC. Content independently developed by OncLive.

Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Two experts in the management of extensive-stage small cell lung cancer provide an overview of chemotherapy-induced myelosuppression and share key insights into the myeloprotective benefit of the CDK4/6 inhibitor trilaciclib.

Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).

Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).

Jennifer Atlas, MD, and Shahab Babakoohi, MD, discuss advances in the treatment of patients with basal cell carcinoma and their treatment approaches to clinical scenarios based on updated data.

An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

Expert provides an overview of esophageal squamous cell carcinoma (ESCC), discusses several key updates to the treatment landscape, and elucidates how clinicians can improve patient outcomes by applying data from the treatment algorithm.

Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.

Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.

Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms. 

Dr. Michael Atkins and Dr. Evan Lipson discuss the state of metastatic melanoma, contemporary and emerging treatment strategies, and break down a specific patient profile. Their conversation touches on the pros and cons of different treatment strategies for newly diagnosed patients as well as second- and third-line treatment strategies. Dr. Atkins and Dr. Lipson also take time to provide their personal experiences, preferences, and thoughts on prospects involving the treatment and management of metastatic melanoma.